Resumo Introdução: As patologias músculo-esqueléticas constituem um dos motivos mais frequentes de consulta em medicina geral e familiar. A elevada incidência destas patologias traduz-se também numa elevada necessidade de cuidados de reabilitação pelo que, em 2021, a prescrição de medicina física e reabilitação (MFR) destacou-se como o segundo maior gasto relativamente ao total da despesa com meios complementares de diagnóstico e terapêutica na região Norte. Assim, importa caracterizar os principais motivos de prescrição. Objetivos: Caracterizar a prescrição de consultas de MFR relativas a patologia osteoarticular e músculo-esquelética no Agrupamento de Centros de Saúde de Matosinhos (ACeS). Métodos: Estudo observacional e retrospetivo de todas as prescrições de MFR realizadas de janeiro a dezembro/2021 em todas as unidades de saúde constituintes de um ACeS, com caracterização sociodemográfica dos utentes e análise do número de prescrições e códigos de Classificação Internacional de Cuidados de Saúde Primários associados às mesmas. Resultados: O número médio de prescrições por USF foi de 1710,07. Verificou-se que 47,94% das prescrições corresponderam a primeira consulta de MFR, enquanto 52,06% corresponderam a consulta subsequente. A maioria das prescrições foi feita a utentes do sexo feminino (65,54%), com isenção do pagamento de taxas moderadoras (58,65%) e idade média de 57,15 anos. O problema de saúde mais frequentemente codificado foi L86 - Síndrome da Coluna com irradiação de dor, seguindo-se L92 - Síndrome do Ombro Doloroso, quer para primeira consulta quer para consulta subsequente. As patologias que originaram maior número de prescrições subsequentes/utente foram esclerose múltipla e parkinsonismo. Observou-se ainda que 46,76% das prescrições se acompanhavam de código ICPC-2 correspondente a diagnóstico passível de prescrição de fisioterapia. Conclusão: Trata-se de um estudo relevante que caracterizou as prescrições de MFR, permitindo conhecer as patologias que levaram à requisição destes cuidados, podendo constituir um ponto de partida para melhorar a adequação dos recursos em saúde.

Abstract Introduction: Musculoskeletal disorders are one of the most frequent reasons for medical appointments in primary care. The high incidence of these pathologies also translates into a high need for rehabilitation care. This is why, in 2021, the prescription of physical and rehabilitation medicine (PRM) stood out as the second highest expense in the total costs of complementary means of diagnostic and therapeutic, in the North of Portugal. Thus, it is important to describe the main reasons for prescription. Objective: To describe the prescriptions of PRM appointments related to osteoarticular and musculoskeletal pathology, in the Matosinhos group of Family Health Units (FHUs). Methods: Observational and retrospective study of all PRM prescriptions carried out from January to December 2021 in 14 FHUs, with sociodemographic characterization of users and analysis of the number of prescriptions and codes of the International Classification of Primary Health Care associated with them. Results: The mean number of prescriptions per FHU was 1710.07. It was found that 47.94% of the prescriptions corresponded to the first PRM appointment, while 52.06% corresponded to the subsequent appointments. Most prescriptions were made to female patients (65.54%), exempted from paying user fees (58.65%), and mean age of 57.15 years. The most frequently coded health problem was L86 - Painful Spine Syndrome, followed by L92 - Painful Shoulder Syndrome, both for first and subsequent appointments. The pathologies that originated the highest number of subsequent prescriptions per user were multiple sclerosis and parkinsonism. It was also observed that 46.76% of the prescriptions were accompanied by an ICPC-2 code corresponding to a valid diagnosis for physiotherapy prescription. Conclusion: This is a relevant study that characterized PRM prescriptions and allowed us to understand the pathologies that led to the need for this care, which may constitute a starting point for improving the adequacy of health resources.

Abstract Objective: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. Diagnosis is based on the Mc-Donalds criteria, magnetic resonance imaging (MRI) studies, and the expanded disability status scale (EDSS) which assesses disease progression. These criteria do not include the recently described cortical lesions. The aim of the study was to describe the most frequent location and morphology of cortical lesions in patients with MS in Puebla, Mexico. Methods: A descriptive, retrospective, cross-sectional, and analytical study was conducted on patients with MS at a tertiary care hospital. Patients diagnosed with relapsing-remitting, secondary-progressive, and progressive-relapsing MS variants with cranial magnetic resonance imaging were included in the study. Age, sex, MS variant, EDSS score, cognitive impairment, annual relapse rate, morphology, location, and number of cortical lesions were evaluated. Descriptive statistics were used. To compare features between groups, the χ2 test was used, and for correlations, the Spearman's Correlation Coefficient was used. A p ≤ 0.05 was considered significant. Results: Twenty-five patients met the selection criteria. The most frequent location of cortical lesions was the parietal region 84%, and the second was the temporal region 16%. The most common morphology was juxtacortical at 64% and mixed at 36%. The most frequent variant of MS was relapsing-remitting, present in 92%, and 8% had the secondary progressive variant. In the EDSS scale, the scores most frequently observed were 0.0 and 3.5. Conclusions: The most frequent location of cortical lesions was in the parietal region, and the most common morphology was juxtacortical.

Resumen Objetivo: La esclerosis múltiple es una enfermedad desmielinizante inflamatoria crónica del sistema nervioso central. El diagnóstico se basa en los criterios de Mc-Donalds, los estudios de Resonancia Magnética y la Escala Expandida del Estado de Discapacidad (EDSS) que evalúa la progresión de la enfermedad. Estos criterios no incluyen las lesiones corticales descritas recientemente. Describir la localización y morfología más frecuente de lesiones corticales en pacientes con esclerosis múltiple en Puebla, México. Métodos: Se realizó un estudio descriptivo, retrospectivo, transversal y analítico en pacientes con esclerosis múltiple en un hospital de tercer nivel de atención. Se incluyeron pacientes con diagnóstico de Esclerosis Múltiple con variantes Remitente-Recurrente, Secundaria-Progresiva y Progresiva-Recurrente con resonancia magnética de cráneo. Se evaluó edad, sexo, variante de esclerosis múltiple, puntaje de EDSS, deterioro cognitivo, tasa de recaída anual, morfología, ubicación y numero de lesiones corticales. Se utilizó estadística descriptiva. Para comparar características entre grupos se utilizó χ2, para correlaciones se utilizó Coeficiente de Correlación de Spearman. Una p ≤ 0.05 se consideró significativa. Resultados: 25 pacientes cumplieron con criterios de selección. La localización más frecuente de lesiones corticales fue la región parietal 84% y la segunda temporal 16%. La morfología más frecuente fue la yuxtacortical en un 64%, y la mixta en 36%. La variante más frecuente de esclerosis múltiple fue Remitente-Recurrente presente en 92%, y 8% la variante Secundaria Progresiva. En la escala de EDDS la puntuación con mayor frecuencia fue 0.0 y 3.5. Conclusiones: La localización más frecuente de las lesiones corticales fue en región parietal y la morfología más frecuente la yuxtacortical.

Resumo O envelhecimento e os transtornos depressivos são fenômenos extremamente complexos, dinâmicos, heterogêneos e fortemente influenciados pelos aspectos biopsicossociais, sendo primordial uma abordagem mais integrada entre as diversas áreas. Este estudo tem como objetivo esboçar um panorama da produção científica sobre os sintomas dos transtornos depressivos em idosos. A coleta de dados foi realizada pela SCOPUS, o software Rayyan retirou as duplicidades e o VOSviewer efetuou as análises bibliométricas. Foram gerados dois bancos para explorar e aprofundar os dados referentes aos sintomas dos transtornos depressivos em idosos e sua dinâmica durante a pandemia da COVID 19, que trouxe modificações diretas e bruscas no comportamento social e psíquico. Os resultados encontrados corroboram com a literatura e teorias referentes ao envelhecimento e saúde mental, reportando sintomas clássicos, associação com as comorbidades e a predominância de pesquisas desenvolvidas pela medicina e suas vertentes. No entanto, também emergiram os termos como “esclerose múltipla”, “diabetes’, “dieta”, “psiquiatria geriátrica” e “sintomas neuropsiquiátricos” sinalizando que existem associações que ainda são pouco exploradas pelos estudos. Os dados bibliométricos indicam que os fenômenos ainda são pesquisados de maneira fragmentada, resultando em uma fraca interconexão entre os termos principais do estudo e os que emergiram na pesquisa. Parece-nos um grande desafio compreender como a teia de sintomas se relacionam e detectar como outras variáveis interferem nos transtornos depressivos em idosos.

Abstract Aging and depressive disorders are extremely complex, dynamic, heterogeneous phenomena that are strongly influenced by biopsychosocial aspects, and a more integrated approach between different areas is essential. This study aims to outline an overview of the scientific production on the symptoms of depressive disorders in the elderly. Data collection was carried out by SCOPUS, the Rayyan software removed duplicates and VOSviewer carried out the bibliometric analyses. Two databases were generated to explore and deepen the data regarding the symptoms of depressive disorders in the elderly and their dynamics during the COVID 19 pandemic, which brought direct and sudden changes in social and psychic behavior. The results found corroborate the literature and theories related to aging and mental health, reporting classic symptoms, association with comorbidities and the predominance of evolutionary trends in medicine and its aspects. However, terms such as “multiple sclerosis”, “diabetes”, “diet”, “geriatric psychiatry” and “neuropsychiatric symptoms” also emerged, signaling that there are associations that are still little explored by studies. Bibliometric data indicate that the phenomena are still researched in a fragmented way, caused by a weak interconnection between the main terms of the study and those that emerged in the research. It seems to us a great challenge to understand how the web of symptoms are related and to detect how other variables interfere with depressive disorders in the elderly.

Abstract Precision medicine has revolutionized the field of neuroimmunology, with innovative approaches that characterize diseases based on their biology, deeper understanding of the factors leading to heterogeneity within the same disease, development of targeted therapies, and strategies to tailor therapies to each patient. This review explores the impact of precision medicine on various neuroimmunological conditions, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), optic neuritis, autoimmune encephalitis, and immune-mediated neuropathies. We discuss advances in disease subtyping, recognition of novel entities, promising biomarkers, and the development of more selective monoclonal antibodies and cutting-edge synthetic cell-based immunotherapies in neuroimmunological disorders. In addition, we analyze the challenges related to affordability and equity in the implementation of these emerging technologies, especially in situations with limited resources.

Resumo A medicina de precisão está revolucionando o campo da neuroimunologia, com uma abordagem inovadora caracterizada pela classificação de doenças com base em sua biologia, compreensão mais profunda dos fatores que levam à heterogeneidade dentro da mesma doença, desenvolvimento de terapias com alvos específicos e estratégias para adaptar as terapias a cada paciente. Esta revisão explora o impacto da medicina de precisão em várias condições neuroimunológicas, incluindo esclerose múltipla (EM), distúrbio do espectro da neuromielite óptica (NMOSD), doença associada ao anticorpo anti-glicoproteína da mielina do oligodendrócito (MOGAD), neurites ópticas, encefalites autoimunes e neuropatias imunomediadas. Discutimos avanços na subclassificação de doenças, reconhecimento de novas entidades, biomarcadores promissores e desenvolvimento de anticorpos monoclonais mais seletivos e imunoterapias de ponta baseadas em células sintéticas para as condições acima. Além disso, analisamos os desafios relacionados com acessibilidade e equidade na implementação dessas tecnologias emergentes, especialmente em ambientes com recursos limitados.

Abstract Background Anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibody-associated disease (MOGAD) is an immune-mediated neurological disorder with a broad spectrum of clinical presentation that is often difficult to distinguish from other demyelinating diseases, such as multiple sclerosis and neuromyelitis optica spectrum disorder. Objective To describe the clinical and paraclinical characteristics of MOGAD in a Brazilian tertiary center. Methods We retrospectively reviewed the records of adult and pediatric patients who tested positive for anti-MOG antibodies and presented with clinical and radiological diseases compatible with MOGAD. Results Forty-one patients (10 children) were included: 56% female, 58% Caucasian, mean age at onset 31 years (range 6-64), with a mean disease duration of 59.6 months (range 1-264 months). The most frequent onset presentation was optic neuritis (68%), acute disseminated encephalomyelitis (ADEM, 12%), and myelitis (10%). A monophasic disease course was observed in 49%. EDSS median was 2.1 at the last visit. Most patients (83%) were under continuous immunosuppressive treatment. Azathioprine was the first-line treatment in 59%. In all ADEM cases, conus, and root involvement was radiologically observed on MRI. Conclusion Brazilian MOGAD patients presented with a similar spectrum of previously reported MOGAD phenotypes. Conus and spinal root involvement seems to be frequently present in MOGAD-ADEM and could serve as radiologic characteristics of this clinical entity.

Resumo Antecedentes A doença associada ao anticorpo da glicoproteína da mielina de oligodendrócitos (anti-MOG; MOGAD) é uma doença neurológica imunomediada com um amplo espectro de apresentações clínicas que muitas vezes é difícil de distinguir de outras doenças desmielinizantes, como a esclerose múltipla e o distúrbio do espectro da neuromielite óptica. Objetivo Descrever as características clínicas e paraclínicas da MOGAD em um centro terciário brasileiro. Métodos Revisamos retrospectivamente os prontuários dos pacientes adultos e pediátricos que testaram positivos para anticorpos anti-MOG e apresentaram um quadro clínico e radiológico compatível com MOGAD. Resultados Quarenta e um pacientes (10 crianças) foram incluídos: 56% do sexo feminino, 58% caucasianos, idade média de início da doença foi 31 anos (intervalo de 6-64), com duração média da doença de 59,6 meses (intervalo de 1-264 meses). A apresentação inicial mais frequente foi neurite óptica (68%), seguida pela encefalomielite disseminada aguda (ADEM, 12%) e mielite (10%). Um curso monofásico da doença foi observado em 49%. EDSS foi de 2,1 na última visita. A maioria dos pacientes (83%) estava sob tratamento imunossupressor contínuo. Azatioprina foi o tratamento de primeira linha em 59%. Em todos os casos de ADEM, o envolvimento do cone medular e das raízes espinhais foi observado radiologicamente na ressonância magnética. Conclusão Os pacientes brasileiros com MOGAD apresentam um espectro clínico e radiológico semelhante aos fenótipos de MOGAD relatados anteriormente. O envolvimento do cone e das raízes espinhais parece estar frequentemente presente no MOGAD-ADEM e poderia servir como característica radiológica nesta entidade.

ABSTRACT Canine distemper causes demyelinating leucoencephalitis, like human multiple sclerosis. The encephalic microenvironment, including the extracellular matrix, is an important key factor of this lesion, already described in multiple sclerosis but not proved in canine distemper. Thereby, the aim of this work is to characterize the extracellular matrix in the encephalon of dogs with canine distemper. Samples of cortex and cerebellum of 14 naturally infected dogs with canine distemper virus were collected after being sent for necropsy in the Animal Pathology Laboratory of the Veterinary Hospital of Uberlândia Federal University. The samples were processed as routine, stained with Hematoxylin and Eosin (H.E), Masson Trichrome (MT), Periodic Acid-Schiff (PAS) and Reticulin, and then described. Areas of demyelination and necrosis were quantified in percentage of stain. The TM samples showed blue stain around vessels and meninge, which indicates a higher deposition of collagen in lesioned areas. At necrotic areas, reticulin stain pointed to a disorganization in the vascular wall and PAS-stained pink granules in macrophages. We conclude that the extracellular matrix seems to participate in the pathogeny of canine distemper. More research should be done to better detail the involvement of these molecules in the course of this disease.

RESUMO A cinomose canina, assim como a esclerose múltipla, provoca leucoencefalite desmeilinizante. O microambiente encefálico, incluindo a matriz extracelular, atua como fator adjuvante na esclerose múltipla, porém não há comprovação do mesmo na cinomose canina. Portanto o objetivo neste trabalho é caracterizar a matriz extracelular do encéfalo de cães com cinomose canina. Foram coletados fragmentos de córtex frontal e cerebelo de 14 cães naturalmente infectados com cinomose canina encaminhados para necropsia no Laboratório de Patologia Animal do Hospital Veterinário da Universidade Federal de Uberlândia. Os fragmentos foram processados rotineiramente, corados com Hematoxilina e Eosina (H.E.), Tricrômico de Masson (TM), Ácido-Periódico de Schiff (PAS) e Reticulina e então foram descritas. As áreas com desmielinização e/ou necrose também foram quantificadas. A coloração de TM evidenciou marcação azulada em vasos e meninge, indicando maior deposição de fibras colágenas nas lesões. Nas áreas de necrose notou-se parede vascular desorganizada, a partir da reticulina, além de pigmentos róseos em macrófagos corados com PAS. Conclui-se que a matriz extracelular aparenta participar na patogenia da cinomose. Outros estudos são necessários para maiores detalhes da ação dessas moléculas na patogenia da cinomose canina.

Abstract Background The prevalence of pain in patients with multiple sclerosis is remarkable. Fibromyalgia has been considered as one of the forms of chronic pain encompassed in multiple sclerosis, but data are restricted to studies from Europe and North America. Objective To assess the prevalence of fibromyalgia in a series of Brazilian patients with multiple sclerosis and the characteristics of this comorbidity. Methods The present cross-sectional study included 60 consecutive adult patients with multiple sclerosis. Upon consent, participants underwent a thorough evaluation for disability, fatigue, quality of life, presence of fibromyalgia, depression, and anxiety. Results The prevalence of fibromyalgia was 11.7%, a figure similar to that observed in previous studies. Patients with the comorbidity exhibited worse scores on fatigue (median and interquartile range [IQR]: 68 [48–70] versus 39 [16.5–49]; p < 0.001), quality of life (mean ± standard deviation [SD]: 96.5 ± 35.9 versus 124.8 ± 28.8; p = 0.021), anxiety (mean ± SD: 22.7 ± 15.1 versus 13.8 ± 8.4; p = 0.021), and depression (median and IQR: 23 [6–28] versus 6 [3–12.5]; p = 0.034) indices than patients without fibromyalgia. There was a strong positive correlation between depression and anxiety scores with fatigue (r = 0.773 and r = 0.773, respectively; p < 0.001). Conversely, a moderate negative correlation appeared between the Expanded Disability Status Scale (EDSS), fatigue, and depression scores with quality of life (r= −0.587, r= −0.551, r= −0.502, respectively; p < 0.001). Conclusion Fibromyalgia is a comorbidity of multiple sclerosis that can enhance fatigue and decrease quality of life, although depression, anxiety, and disability are factors that can potentiate the impact of the comorbidity.

Resumo Antecedentes A prevalência de dor em pacientes com esclerose múltipla é significativa. A fibromialgia é considerada uma forma de dor crônica encontrada na esclerose múltipla, mas os dados são restritos a estudos europeus e da América do Norte. Objetivo Avaliar a prevalência de fibromialgia em uma série de pacientes com esclerose múltipla e as características desta comorbidade. Métodos O presente estudo transversal incluiu consecutivamente 60 pacientes adultos com esclerose múltipla. Após o consentimento, os participantes foram submetidos à avaliação para determinação de incapacidade, fadiga, qualidade de vida, presença de fibromialgia, depressão e ansiedade. Resultados A prevalência de fibromialgia foi de 11,7%, similar ao observado em estudos prévios. Pacientes com a comorbidade apresentaram piores escores de fadiga (mediana e intervalo interquartil [IIQ]: 68 [48–70] versus 39 [16,5–49]; p < 0,001], qualidade de vida (média ± desvio padrão [DP]: 96,5 ± 35,9 versus 124,8 ± 28,8; p = 0,021), ansiedade (média ± DP: 22,7 ± 15,1 versus 13,8 ± 8,4; p = 0,021) e depressão (mediana e IIQ: 23 (6–28) versus 6 (3–12,5); p = 0,034] do que pacientes sem fibromialgia. Houve correlação positiva forte dos escores de depressão e de ansiedade com a fadiga (r = 0,773 e r = 0,773, respectivamente; p < 0,001). Concomitantemente, houve correlação negativa moderada entre os escores de escala de estado de incapacidade expandida, fadiga e depressão com a qualidade de vida (r = - 0,587, r = - 0,551, r = - 0,502, respectivamente; p < 0,001). Conclusão A fibromialgia é uma comorbidade de esclerose múltipla que pode aumentar a fadiga e diminuir a qualidade de vida, embora depressão, ansiedade e incapacidade sejam fatores potencializadores dessa morbidade associada.

Resumen Introducción : El objetivo fue evaluar la inmunogeni cidad y efectividad de las vacunas contra el SARS-CoV-2 en pacientes con esclerosis múltiple (EM) incluidos en el registro argentino de EM (RelevarEM, NCT 03375177). Métodos : Estudio de cohorte prospectivo entre mayo y diciembre 2021. Se evaluó la inmunogenicidad (detec ción de anticuerpos totales (Ab) contra proteína espiga y anticuerpos neutralizantes en suero) y eficacia (nueva infección por COVID-19) durante seguimiento de tres meses. El momento de detección de anticuerpos fue 4 semanas después de segunda dosis de vacuna. Un caso positivo de COVID-19 se definió de acuerdo con la defi nición del Ministerio de Salud. Resultados : Se incluyeron 94 pacientes, edad media de 41.7 ± 12.1 años. Ochenta (85.1%) tenían EM remiten te-recurrente; 30 (31.9%) en tratamiento con fingolimod. La vacuna Sputnik V fue usada en 33 (35.1%), mientras que AstraZeneca se administró en 61 (64.9%). En 60 pa cientes (63.8 %), la vacuna provocó respuesta humoral específica. La respuesta inmunológica según esquemas de vacunación (Sputnik V, Astra Zeneca o esquemas he terólogos) no mostró diferencias cualitativas (p = 0.45). El análisis estratificado según tratamiento recibido para la EM mostró que número significativamente menor de sujetos desarrolló anticuerpos contra el antígeno espiga en los pacientes que recibieron ocrelizumab (p ≤ 0.001), aunque con un número reducido de pacientes evaluados bajo este tratamiento (n = 7). Esto también se observó para anticuerpos neutralizantes en el grupo bajo ocrelizumab (p < 0.001). Durante el seguimiento de tres meses, dos personas fueron diagnosticadas con COVID-19. Conclusión : Encontramos que los pacientes con EM que recibieron vacunas Sputnik V o AstraZeneca para el SARS-CoV-2 desarrollaron respuesta serológica sin diferencias entre las vacunas utilizadas.

Abstract Introduction : The objective was to assess the im munogenicity and effectiveness of vaccines against SARSCoV-2 in multiple sclerosis (MS) patients included in the Argentinean MS registry. Methods : A prospective cohort study between May and December 2021. The primary outcome was im munogenicity and effectiveness of vaccines during a three-month follow-up. Immunogenicity was evalua ted based on detection of total antibodies (Ab) against spike protein and neutralizing Ab in serum 4 weeks after the second vaccine dose. A positive COVID-19 case was defined according to Argentinean Ministry of Health. Results : 94 patients were included, mean age: 41.7 ± 12.1 years. Eighty (85.1%) had relapsing remitting mul tiple sclerosis (RRMS); 30 (31.9%) were under fingolimod treatment. The Sputnik V vaccine was the first dose in 33 (35.1%), and AstraZeneca in 61 (64.9%). In 60 (63.8%), the vaccine elicited a specific humoral response. Immu nological response according to the vaccination schemes showed no qualitative differences (p = 0.45). Stratified analysis according to the MS treatment showed that a significantly smaller number of subjects developed anti bodies against spike antigen among those that were on ocrelizumab compared to other groups (p ≤ 0.001), while a reduced number of patients under ocrelizumab where evaluated (n = 7). This was also observed for neutralizing antibodies in the ocrelizumab group (p < 0.001). During the three-month follow-up, two individuals were diag nosed with COVID-19. Conclusion: We found that MS patients that recei ved Sputnik V or AstraZeneca vaccines for SARS-CoV-2 developed a serological response with no differences between the vaccines used.

Resumen Introducción: el Treatment Burden Questionnaire (TBQ) evalúa la carga que implica el autocuidado de personas con enfermedades crónicas y el impacto que la asistencia sanitaria genera en su calidad de vida. Objetivos: adaptar y validar psicométricamente la versión en español del cuestionario TBQ-esclerosis múltiple al contexto de la diabetes mellitus (DM) en pacientes atendidos en el sector público de Argentina. Materiales y métodos: estudio analítico de adaptación transcultural y validación psicométrica de un cuestionario. Se realizó un análisis factorial exploratorio (AFE) y un análisis factorial confirmatorio (AFC). La validez de criterio concurrente se evaluó a través de la correlación Pearson con tres escalas (OMS-5, PHQ-9 y test de Morisky-Green). La fiabilidad se analizó a través del coeficiente alfa de Cronbach, de la fiabilidad compuesta y la varianza media extractada. Resultados: participaron 256 personas. La versión adaptada fue adecuadamente comprendida por la población destinataria. El AFE (n=100) permitió hipotetizar cuatro dominios: 1) tratamiento farmacológico; 2) asistencia sanitaria/sistema de salud; 3) mantenimiento de un estilo de vida y su repercusión económica; 4) esfera psicosocial. En el AFC (n=156) las cargas factoriales del 87,5% (14/16) de los ítems fueron mayores a 0,5 con significancia estadística. Se documentó correlación inversa (-0,46; p=0,0002) con el puntaje OMS-5 y directa (0,36; p=0,0046) con PHQ-9. Los pacientes categorizados como “no adherentes” mediante la escala de Morisky-Green-Levine arrojaron un resultado de TBQ-DM de 16,99 (IC 95%: 0,95 a 33,03) puntos más que los pacientes categorizados como “adherentes” (p=0,0383). La consistencia interna del cuestionario fue muy buena (alfa de Cronbach: 0,87), su fiabilidad compuesta fue aceptable y su validez divergente, baja. Conclusiones: el TBQ en español adaptado a DM2 tiene aceptables propiedades psicométricas. Su implementación podría ofrecer cuidados basados en la persona.

Abstract Introduction: the Treatment Burden Questionnaire (TBQ) assess the load that implies the self-care for people with chronic diseases and the impact that medical assistance produce in their quality of life. Objectives: to adapt and psychometrically validate the spanish version of the TBQ-multiple sclerosis questionnaire to the diabetes mellitus (DM) context in patients treated in the Argentinian public health sector. Materials and methods: analytic study of transcultural adaptation and psychometric validation of a questionnaire. An exploratory factor analysis (EFA) and a confirmatory factor analysis (CFA) were performed. Concurrent criterion validity was evaluated through Pearson correlation with three scales (WHO-5, PHQ-9, Morisky-Green Test). Reliability was evaluated through Cronbach's alpha coefficient, composite reliability, and average variance extracted. Results: 256 people participated. The adapted version was adequately understood by the target population. EFA (n=100) allowed for the hypothesis of four domains: 1) pharmacological treatment; 2) healthcare/health system; 3) maintenance of a lifestyle and its economic impact; 4) psychosocial sphere. In the CFA (n=156), the factor loadings of 87.5% (14/16) of the items were greater than 0.5 with statistical significance. An inverse correlation (-0.46; p=0.0002) with the WHO-5 index and a direct correlation (0.36; p=0.0046) with the PHQ-9 scale were documented. Patients categorized as “non-adherent” by the Morisky-Green-Levine scale had a TBQ-DM score of 16.99 (95% CI: 0.95 to 33.03) points higher than patients categorized as “adherent” (p=0.0383). The internal consistency of the questionnaire was very good (Cronbach's alpha: 0.87), its composite reliability was acceptable, and its divergent validity was low. Conclusions: the spanish TBQ adapted to DM2 has acceptable pyshcometric properties. Its implementation can help offer a person-centered care.

Abstract The spectrum of neuropsychiatric phenomena observed in amyotrophic lateral sclerosis (ALS) is wide and not fully understood. Disorders of laughter and crying stand among the most common manifestations. The aim of this study is to report the results of an educational consensus organized by the Brazilian Academy of Neurology to evaluate the definitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in ALS patients. Twelve members of the Brazilian Academy of Neurology - considered to be experts in the field - were recruited to answer 12 questions about the subject. After exchanging revisions, a first draft was prepared. A face-to-face meeting was held in Fortaleza, Brazil on 9.23.22 to discuss it. The revised version was subsequently emailed to all members of the ALS Scientific Department from the Brazilian Academy of Neurology and the final revised version submitted for publication. The prevalence of pseudobulbar affect/pathological laughter and crying (PBA/PLC) in ALS patients from 15 combined studies and 3906 patients was 27.4% (N = 1070), ranging from 11.4% to 71%. Bulbar onset is a risk factor but there are limited studies evaluating the differences in prevalence among the different motor neuron diseases subtypes, including patients with and without frontotemporal dementia. Antidepressants and a combination of dextromethorphan and quinidine (not available in Brazil) are possible therapeutic options. This group of panelists acknowledge the multiple gaps in the current literature and reinforces the need for further studies.

Resumo O espectro de fenômenos neuropsiquiátricos observados na ELA é amplo e não completamente entendido. Desordens do riso e do choro estão entre as manifestações mais comuns. O objetivo deste estudo é relatar os resultados de um Consenso organizado pela Academia Brasileira de Neurologia para avaliar definições, fenomenologia, diagnóstico, e manejo dos distúrbios do riso e do choro em pacientes com ELA. Doze membros da Academia Brasileira de Neurologia – considerados experts na área – foram recrutados para responder 12 questões na temática. Depois da verificação das revisões, um primeiro manuscrito foi preparado. Após, foi realizado um encontro presencial em Fortaleza, Brasil, em 23/09/2022, para discussão do conteúdo. A versão revisada foi posteriormente enviada por e-mail para todos os membros do Departamento Científico de DNM/ELA da Academia Brasileira de Neurologia e a versão final revisada foi submetida para publicação. A prevalência da síndrome pseudobulbar em pacientes com ELA em 15 estudos combinados com 3906 pacientes foi de 27,4% (n = 1070), variando entre 11,4% e 71%. Início bulbar é um fator de risco, mas há limitados estudos avaliando as diferenças em prevalência entre os diferentes subtipos de Doença do Neurônio Motor, incluindo pacientes com e sem Demência Frontotemporal. Antidepressivos e uma combinação de dextrometorfana e quinidina (indisponíveis no Brasil) são opções terapêuticas possíveis. Esse grupo de panelistas reconhece as múltiplas demandas não atendidas na literatura atual e reforça a necessidade de futuros estudos.

Resumen Antecedentes: La esclerosis múltiple es una enfermedad crónica, autoinmune y degenerativa. Las terapias blanco contra los linfocitos B han probado ser efectivas en su tratamiento; sin embargo, existen pocos estudios que evalúen su eficacia en población mexicana. Objetivo: Evaluar el impacto clínico del rituximab en pacientes con esclerosis múltiple remitente recurrente (EMRR) de reciente diagnóstico. Material y métodos: Estudio de vida real, descriptivo, en el que se evalúa rituximab como tratamiento de EMRR durante un periodo de 24 meses. Se analizaron variables clínicas pre y postratamiento; se realizó la comparación entre pacientes naïve y no naïve. Resultados: Se incluyeron 28 pacientes con EMRR. La edad media al diagnóstico fue de 30.7 años y 22 pacientes fueron naïve (78.5 %). Después de 24 meses, se observó una reducción media de 1.8 puntos en EDSS y en el número de lesiones activas por resonancia magnética. Aunque se logró establecer una diferencia significativa en ambas variables con p < 0.05, el modelo de regresión logística no mostró una relación entre las variables para alcanzar un NEDA-3. No se observaron eventos adversos graves. Conclusiones: El tratamiento con rituximab resultó en mejoría significativa clínica y radiológica en pacientes mexicanos con EMRR naïve y no-naïve.

Abstract Background: Multiple sclerosis is a chronic, autoimmune, degenerative disease. Therapies targeting B-cells have been shown to be effective in its treatment; however, there are few studies evaluating their efficacy in the Mexican population. Objective: To evaluate the clinical impact of rituximab in patients with newly-diagnosed relapsing-remitting multiple sclerosis (RRMS). Material and methods: Real life, descriptive study, in which rituximab was evaluated as treatment for RRMS over a 24-month period. Pre- and post-treatment clinical variables were analyzed; a comparison was made between treatment-naïve and non-treatment-naïve patients. Results: Twenty-eight patients with RRMS were included. Mean age at diagnosis was 30.7 years, and 22 patients were treatment-naïve (78.5 %). After 24 months, there was a mean reduction of 1.8 points in the EDSS scale and a decrease in the number of active lesions on magnetic resonance imaging; a significant difference in both variables could be established (p < 0.05). However, the logistic regression model did not show a relationship between the variables for achieving NEDA-3 criteria. No serious adverse events were observed. Conclusions: Treatment with rituximab resulted in significant clinical and radiological improvement in treatment-naïve and non-treatment-naïve Mexican patients with RRMS.

ABSTRACT Introduction: Multiple sclerosis (MS) is a chronic, neurodegenerative, inflammatory disease of the central nervous system (CNS) that significantly compromises cognitive functions. In Paraguay, it occurs with a prevalence of 9.2/100,000 inhabitants, 72% in the clinical form of relapsing remission (RRMS) and an incidence of 2 to 3 women/men, affecting more people of productive age with high economic and emotional costs. Objectives: To characterize the Paraguayan patient with RRMS, to assess the state of their executive functions (EFs) with the BaNFE-2 battery, and to establish cut-off values adjusted to the country. Methods: Research based on the theory of cognitive neuroscience of non-experimental, quantitative and descriptive design for analytical purposes. It is empirical, retrospective and cross-sectional. The psychometric technique and neuropsychological interview were used in a convenience sample of 40 patients aged 25 to 55 (37.78 ± 7.89) and 82.5% women. Results: Demographic and clinical data of the participants were reported. The BaNFE-2 coded and normalized scales were statistically characterized, the internal consistency of which was significant. 52.5% of the alteration was obtained in the anterior prefrontal scale and 42.5% in FEs; there are significant relationships with schooling, physical disability (PD), number of outbreaks and cognitive impairment (CI); there were also significant differences by sex, education, PD and CI. Standardized scores adjusted for schooling were calculated such that z<-1 establishes the cutoff between normality and abnormality. Conclusion: BaNFE-2 battery tests profile the affectation of execution time, attention, working memory, and FEs. This study provides the adjusted scales for the country and opens a new line of research applying the BaNFE-2 battery in people with MS.

RESUMEN Introducción: la esclerosis múltiple (EM), enfermedad crónica del sistema nervioso (SNC), compromete significativamente la cognición. Su prevalencia en Paraguay es 9,2/100.000 habitantes, 72% con recaída remisión (EMRR) e incidencia de 2-3mujeres/hombre, afecta más a personas en edad productiva, con altos costos económicos y afectivos. Objetivos: caracterizar al paciente con EMRR, evaluar sus funciones ejecutivas (FEs) con BaNFE-2; establecer valores de corte ajustados al país. Metodología: con fundamento en teoría de la neurociencia cognitiva, diseño no experimental, cuantitativo, descriptivo, empírico, retrospectivo y transversal; técnica psicométrica y entrevista neuropsicológica en una muestra por conveniencia de 40 pacientes, 82,5% mujeres y edad 25-55 años (37,78±7,89). Resultados: se reportaron datos demográficos y clínicos, se caracterizaron las escalas de BaNFE-2 cuya consistencia interna resultó significativa. Se obtuvo 52,5% de alteración en la escala prefrontal y 42,5% en FEs; relaciones significativas con escolaridad, discapacidad física (DF), cantidad de brotes y deterioro cognitivo (DC); diferencias significativas por sexo, escolaridad, DF y DC. Se calcularon puntuaciones tipificadas por escolaridad, z<-1 establece el corte entre normalidad y alteración. Conclusión: las pruebas de BaNFE-2 perfilan la afectación del tiempo de ejecución, atención, memoria de trabajo y FEs. Este estudio aporta baremos ajustados al país y abre una novedosa línea de investigación aplicando BaNFE-2 en EM.

Resumo A esclerose múltipla (EM) é uma doença do sistema nervoso central (SNC) caracterizada por inflamação, desmielinização axonal e neurodegeneração, que pode ter um forte impacto em todos os aspectos da vida dos pacientes. A EM causa disfunções motoras, sensoriais, cerebelares, autonômicas, comprometimento cognitivo e déficits psicoemocionais. Os domínios cognitivos mais frequentemente comprometidos são a atenção complexa/processamento da informação, memória, funções executivas e habilidades visuais-espaciais. Recentemente, também foram evidenciadas alterações em funções cognitivas complexas, como cognição social, julgamento moral e tomada de decisão. O comprometimento cognitivo é caracterizado por alta variabilidade e pode afetar as habilidades laborais, as interações sociais, as estratégias de enfrentamento e, de forma mais geral, a qualidade de vida dos pacientes e de seus familiares. Com o uso de baterias de testes sensíveis e fáceis de administrar, é viável um diagnóstico cada vez mais preciso e precoce: isso permite determinar a eficácia de possíveis medidas preventivas, prever a progressão futura da doença e melhorar a qualidade de vida dos pacientes. Atualmente, há evidências limitadas sobre a eficácia, no comprometimento cognitivo, de terapias modificadoras da doença. A abordagem mais promissora, que tem recebido forte apoio empírico, é a reabilitação cognitiva. (EM SNC (SNC inflamação neurodegeneração motoras sensoriais cerebelares autonômicas psicoemocionais complexaprocessamento complexa processamento informação memória visuaisespaciais. visuaisespaciais visuais espaciais. espaciais visuais-espaciais Recentemente complexas social decisão laborais sociais geral familiares administrar precoce preventivas Atualmente promissora empírico cognitiva

Abstract Multiple sclerosis (MS) is a central nervous system (CNS) disease characterized by inflammation, axonal demyelination, and neurodegeneration, which can have a strong impact on all aspects of the life of the patient. Multiple sclerosis causes motor, sensory, cerebellar, and autonomic dysfunctions, as well as cognitive and psychoemotional impairment. The most frequently compromised cognitive domains are complex attention/information processing, memory, executive and visuospatial functions. Recently, alterations have also been evidenced in complex cognitive functions, such as social cognition, moral judgment, and decision-making. Cognitive impairment is characterized by high variability and can affect work skills, social interactions, coping strategies and more generally the quality of life of patients and their families. With the use of sensitive and easy-to-administer test batteries, an increasingly accurate and early diagnosis is feasible: this allows to determine the effectiveness of possible preventive measures, to predict the future progression of the disease and to improve the quality of life of patients. There is currently limited evidence regarding the efficacy, on cognitive impairment, of disease-modifying therapies. The most promising approach, which has received strong empirical support, is cognitive rehabilitation. MS (MS CNS (CNS inflammation demyelination neurodegeneration patient motor sensory cerebellar dysfunctions attentioninformation attention information processing memory functions Recently cognition judgment decisionmaking. decisionmaking decision making. making decision-making skills interactions families easytoadminister easy administer batteries feasible measures efficacy diseasemodifying modifying therapies approach support rehabilitation

RESUMEN: El cuerpo calloso (CC) incluye la mayoría de las fibras que unen los dos hemisferios cerebrales. Varios estudios transversales mostraron una asociación entre la atrofia y el mal funcionamiento calloso y las enfermedades neurodegenerativas, lo que puede desempeñar un papel en sus manifestaciones patológicas. En consecuencia, la cuantificación precisa del cuerpo calloso es importante para tener valores normativos según sexo, edad y etnia. El propósito de este estudio fue determinar el tamaño de CC en pacientes que padecen esclerosis múltiple y compararlo con el tamaño de CC en individuos sanos. El tamaño sagital medio del CC se registró prospectivamente a partir de 404 exámenes cerebrales de RM de rutina en individuos normales. Se midió la superficie interna del cráneo para calcular la relación CC/superficie interna del cráneo. Se estudiaron dos grupos de pacientes: 200 (100 hombres/100 mujeres) sanos y 204 (101 hombres/103 mujeres) con esclerosis múltiple (EM). El área superficial media de CC en los controles fue de 6,58±1,04 cm2 y no hubo diferencia significativa entre hombres y mujeres (P< 0,627). La relación CC/superficie interna del cráneo fue de 4,44±0,77 %. Los pacientes con EM mostraron una disminución significativa en el tamaño de CC en comparación con los controles normales. Usando imágenes de RM, medimos los tamaños medios de las diversas porciones del CC en individuos normales, además de pacientes con EM; estos valores pueden proporcionar una base útil para determinar los cambios que ocurren en las estructuras CC.

SUMMARY: The corpus callosum (CC) includes the majority of fibers linking the two brain hemispheres. Several cross sectional studies showed an association between callosal atrophy and malfunction and neurodegenerative diseases, which may play a role in their pathological manifestations. As a result, the accurate quantification of the corpus callosum is important to have normative values according to sex, age and ethnicity. The purpose of this study is to determine the size of CC in patients suffering from multiple sclerosis, and compare it to CC size in healthyindividuals. Midsagittal size of CC were recorded prospectively from 404 routine MR brain examinations in normal individuals. The internal skull surface was measured to calculate CC/ internal skull surface ratio. Two groups of patients were studied: 200 (100 male /100 female) healthy individuals and 204 (101 males/103 females) with multiple sclerosis (MS). Mean surface area of CC in controls was 6.58±1.04 cm2 and there was no significant difference between males and females (P< 0.627). CC/ internal skull surface ratio was 4.44±0.77 %. MS patients showed a significant decrease in CC size compared to normal controls. Using MR imaging, we measured the mean sizes of the various portions of the CC in normal individuals, in addition to MS patients; these values may provide a useful basis to determine changes occurring in CC structures.